The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback